Last updated: February 20, 2026
What is Darifenacin Hydrobromide?
Darifenacin hydrobromide is a selective antagonist of the M3 muscarinic receptor, primarily used for the treatment of overactive bladder (OAB). It was developed by Pfizer and approved by the U.S. FDA in 2007. The drug's mechanism involves reducing bladder muscle spasms by inhibiting parasympathetic signals, leading to increased bladder capacity and decreased urgency.
Market Size and Growth Drivers
The global overactive bladder treatment market was valued at approximately $3.2 billion in 2022. It is projected to reach $4.6 billion by 2030, with a compound annual growth rate (CAGR) of 4.7% from 2023 onwards (Grand View Research, 2022).
Darifenacin's market share has historically been below 10%, primarily due to competition from other antimuscarinics and newer agents such as beta-3 adrenergic receptor agonists. The drug's specific profile, including a favorable side effect profile compared to less selective agents, sustains its relevance.
Competitive Landscape
Key Drugs in the OAB Class
| Drug Name |
Market Entry Year |
Key Features |
Estimated Market Share (%) (2022) |
| Solifenacin (Vesicare) |
2008 |
High selectivity for M3 receptors |
15 |
| Trospium (Sanctura) |
2006 |
Quaternary amine, fewer CNS side effects |
10 |
| Oxybutynin (Ditropan) |
1978 |
First-generation antimuscarinic, broad action |
20 |
| Mirabegron (Myrbetriq) |
2012 |
Beta-3 receptor agonist, non-antimuscarinic |
25 |
| Darifenacin |
2007 |
Selective for M3 receptors, once daily dose |
8 |
Patent and Regulatory Status
Pfizer's patent for darifenacin expired in the U.S. in 2014, opening the market to generics. Several generic versions entered the market in 2015, leading to significant price erosion. In Europe and Asia, patent protection extended until 2016–2018 in some jurisdictions.
Off-Patent Competition and Biosimilars
Post-patent expiry, generic formulations have captured approximately 80% of the U.S. market for darifenacin, mainly due to price competition. No biosimilars exist, as the drug is small-molecule.
Pricing and Revenue Trends
Historical Pricing
| Year |
Average Wholesale Price (AWP) per 30 tablets |
Notes |
| 2010 |
$250 |
Brand-name only |
| 2014 |
$180 |
Price decline before generics |
| 2016 |
$90 |
Post-generic entry |
| 2022 |
$60 |
Market consolidation |
Revenue Trajectory
Pfizer's peak annual sales (2011–2013) approached $150 million. Current revenues from darifenacin are negligible post-generic competition, with market sales in the U.S. estimated at under $10 million annually.
Regulatory and R&D Pipeline
Pfizer's patent expiration led to the withdrawal of the original product from some markets. No recent regulatory filings or new formulations for darifenacin are reported, indicating limited R&D activity on this molecule. Industry focus has shifted toward combination therapies and agents targeting beta-3 receptors.
Future Market Outlook
The OAB market growth relies on aging populations and increased diagnosis. Entry of newer non-antimuscarinic agents limits demand for darifenacin. Clinical trials on combination therapies or novel delivery methods for existing drugs could impact the competitive landscape.
In markets where brand loyalty persists, especially among patients intolerant to other medications, darifenacin retains niche value. However, price sensitivity and generic availability suppress revenue potential significantly.
Key Takeaways
- Darifenacin hydrobromide's initial market was approximately $150 million annually in peak years.
- Patent expiration in 2014 led to immediate generic competition, eroding revenue sources.
- Current market sales are minimal, mainly driven by generics with low pricing.
- The broader OAB treatment market continues to grow, but darifenacin's share is limited due to competition from newer agents.
- No recent significant R&D efforts or formulations are announced, reflecting diminished strategic focus.
FAQs
1. Is darifenacin hydrobromide still available commercially?
Yes, generic versions are available, mainly in the U.S. and Europe, but the original branded version is less prominent.
2. How does darifenacin compare to beta-3 receptor agonists?
It targets muscarinic receptors selectively, whereas beta-3 agonists like mirabegron act via different pathways, often offering fewer anticholinergic side effects.
3. What factors influence darifenacin's marketability?
Patent expiry, competition from generics and newer agents, pricing, and physician prescribing habits.
4. Are there ongoing developments for darifenacin?
No significant new formulations or trials have been reported in recent years.
5. What is the outlook for darifenacin in emerging markets?
Market penetration depends on regulatory approvals and pricing policies; generic availability may facilitate some demand.
Sources:
[1] Grand View Research. (2022). Overactive Bladder Market Size, Share & Trends Analysis Report.
[2] U.S. Food and Drug Administration. (2007). FDA Approval for Daranifenacin.
[3] IQVIA. (2022). Pharmaceutical Market Data.
[4] European Medicines Agency. (2016). Summary of Product Characteristics.
